Alliance Pharma - APH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: GBX 80.75
  • Forecasted Upside: 110.31%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 38.40
▲ +1.145 (3.07%)

This chart shows the closing price for APH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alliance Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APH

Analyst Price Target is GBX 80.75
▲ +110.31% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Alliance Pharma in the last 3 months. The average price target is GBX 80.75, with a high forecast of GBX 105 and a low forecast of GBX 53. The average price target represents a 110.31% upside from the last price of GBX 38.40.

This chart shows the closing price for APH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Alliance Pharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/31/2024Royal Bank of CanadaLower TargetOutperformGBX 65 ➝ GBX 60
9/26/2023Peel HuntReiterated RatingHoldGBX 53
5/25/2023Numis SecuritiesReiterated RatingBuyGBX 105
5/25/2023Berenberg BankReiterated RatingBuyGBX 105
3/17/2023Peel HuntInitiated CoverageHoldGBX 65
2/1/2023Numis SecuritiesReiterated RatingBuyGBX 110
1/17/2023Berenberg BankLower TargetBuyGBX 110 ➝ GBX 105
9/20/2022Berenberg BankReiterated RatingBuyGBX 145
8/8/2022Royal Bank of CanadaReiterated RatingOutperformGBX 130
7/14/2022Berenberg BankReiterated RatingBuyGBX 145
6/15/2022Berenberg BankReiterated RatingBuyGBX 145
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 130
1/28/2022Royal Bank of CanadaBoost TargetOutperformGBX 106 ➝ GBX 121
6/29/2021Numis SecuritiesReiterated RatingBuyGBX 120
6/3/2019Numis SecuritiesReiterated RatingBuy
5/24/2019Numis SecuritiesReiterated RatingBuyGBX 115
5/16/2019Numis SecuritiesReiterated RatingBuy
5/1/2019Numis SecuritiesUpgradeBuy
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/16/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Alliance Pharma logo
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Read More

Today's Range

Now: GBX 38.40
Low: 37
High: 38.40

50 Day Range

MA: GBX 39.31
Low: 36.35
High: 44.80

52 Week Range

Now: GBX 38.40
Low: 33.70
High: 73.04

Volume

36,294 shs

Average Volume

765,663 shs

Market Capitalization

£207.49 million

P/E Ratio

N/A

Dividend Yield

3.75%

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Alliance Pharma?

The following Wall Street sell-side analysts have issued reports on Alliance Pharma in the last twelve months: Berenberg Bank, Numis Securities Ltd, Peel Hunt, and Royal Bank of Canada.
View the latest analyst ratings for APH.

What is the current price target for Alliance Pharma?

4 Wall Street analysts have set twelve-month price targets for Alliance Pharma in the last year. Their average twelve-month price target is GBX 80.75, suggesting a possible upside of 116.8%. Numis Securities Ltd has the highest price target set, predicting APH will reach GBX 105 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 53 for Alliance Pharma in the next year.
View the latest price targets for APH.

What is the current consensus analyst rating for Alliance Pharma?

Alliance Pharma currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for APH.

What other companies compete with Alliance Pharma?

How do I contact Alliance Pharma's investor relations team?

Alliance Pharma's physical mailing address is Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom. The company's listed phone number is +44-1249-466966. The official website for Alliance Pharma is www.alliancepharma.co.uk. Learn More about contacing Alliance Pharma investor relations.